Pharmagreen Biotech Stock Shares Owned By Insiders
PHBI Stock | USD 0 0.0001 5.26% |
Pharmagreen Biotech fundamentals help investors to digest information that contributes to Pharmagreen Biotech's financial success or failures. It also enables traders to predict the movement of Pharmagreen Pink Sheet. The fundamental analysis module provides a way to measure Pharmagreen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmagreen Biotech pink sheet.
Pharmagreen |
Pharmagreen Biotech Company Shares Owned By Insiders Analysis
Pharmagreen Biotech's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Pharmagreen Biotech Shares Owned By Insiders | 18.63 % |
Most of Pharmagreen Biotech's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmagreen Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 18.63% of Pharmagreen Biotech are shares owned by insiders. This is 22.73% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by insiders for all United States stocks is 84.64% lower than that of the firm.
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
All Next | Launch Module |
Pharmagreen Fundamentals
Return On Asset | -2.3 | |||
Current Valuation | 3.12 M | |||
Shares Outstanding | 454.76 M | |||
Shares Owned By Insiders | 18.63 % | |||
EBITDA | (828.26 K) | |||
Net Income | (875.48 K) | |||
Cash And Equivalents | 24.26 K | |||
Total Debt | 119.47 K | |||
Current Ratio | 0.10 X | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (426.57 K) | |||
Earnings Per Share | (0.01) X | |||
Beta | 1.44 | |||
Market Capitalization | 2.96 M | |||
Total Asset | 208.97 K | |||
Z Score | 4.5 | |||
Net Asset | 208.97 K |
About Pharmagreen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmagreen Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmagreen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmagreen Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmagreen Pink Sheet
Pharmagreen Biotech financial ratios help investors to determine whether Pharmagreen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmagreen with respect to the benefits of owning Pharmagreen Biotech security.